Ceftaroline

A fifth-generation cephalosporin antibacterial agent that is used to treat skin infections caused by bacteria in adults and newborns. Ceftaroline has a 1,3-thiazolidine ring attached to the C-7 position of its cephalosporin core.

Also Known As:

Networked: 469 relevant articles (73 outcomes, 115 trials/studies)

Relationship Network

Drug Context: Research Results

Experts

1.	Sader, Helio S: 31 articles (01/2021 - 06/2010)
2.	Jones, Ronald N: 31 articles (11/2017 - 06/2010)
3.	Rybak, Michael J: 22 articles (03/2022 - 11/2009)
4.	Friedland, H David: 22 articles (06/2019 - 09/2010)
5.	Flamm, Robert K: 20 articles (12/2018 - 09/2012)
6.	Farrell, David J: 15 articles (08/2016 - 04/2011)
7.	Mendes, Rodrigo E: 14 articles (01/2021 - 11/2010)
8.	Jandourek, Alena: 14 articles (06/2019 - 05/2010)
9.	Biek, Donald: 14 articles (07/2016 - 09/2008)
10.	Stone, Gregory G: 12 articles (02/2022 - 01/2019)

Related Diseases

1.	Infections 09/01/2008 - "Ceftaroline was very potent against bacteria found in community- and hospital-acquired infections, including methicillin-resistant Staphylococcus aureus, multidrug-resistant Streptococcus pneumoniae, and common Enterobacteriaceae spp." 10/01/2017 - "Ceftaroline efficacy against high-MIC clinical Staphylococcus aureus isolates in an in vitro hollow-fibre infection model." 03/01/2014 - "Although a non-inferiority design was used for these clinical trials, some data suggest a superior efficacy of ceftaroline, with earlier clinical response and higher cure rate in infections caused by S. " 07/01/2011 - "Ceftaroline was effective against the 4 isolates tested and may provide a clinical option for the treatment of DNS MRSA infections." 02/01/2013 - "Ceftaroline can be a safe and effective drug for treatment of severe MRSA infections, and further comparative studies are warranted."
2.	Endocarditis 04/01/2021 - "Twenty-two of thirty-five (62.8%) patients prescribed ceftaroline because of failure of previous treatment improved, including eight endocarditis and seven bacteraemia. " 05/01/2019 - "Ceftaroline fosamil for the treatment of Gram-positive endocarditis: CAPTURE study experience." 01/01/2017 - "The clinical resolution of MRSAB or SAB in patients who received ceftaroline ranged from 31.0% to 83.3%; studies used varying definitions for clinical resolution and included differing proportions of patients with endocarditis. " 01/01/2017 - "In multiple studies, ceftaroline has displayed rapid bloodstream eradication, even in the setting of refractory MRSAB or infective endocarditis. " 05/01/2022 - "Incidence and risk factors for mortality in patients treated with combined ceftaroline for Gram-positive infective endocarditis."
3.	Pneumonia (Pneumonitis) 01/01/2022 - "Subgroup analyses of the primary endpoint demonstrated consistency of favourable efficacy of ceftaroline fosamil across age groups, Pneumonia Outcomes Research Team risk classes and CURB-65 scores. " 12/01/2012 - "Efficacy of ceftaroline fosamil in a staphylococcal murine pneumonia model." 06/09/2019 - "Efficacy and Safety of Ceftaroline for the Treatment of Community-Acquired Pneumonia: A Systemic Review and Meta-Analysis of Randomized Controlled Trials." 04/01/2011 - "Comparative ceftaroline activity tested against pathogens associated with community-acquired pneumonia: results from an international surveillance study." 04/01/2011 - "Integrated safety summary of FOCUS 1 and FOCUS 2 trials: Phase III randomized, double-blind studies evaluating ceftaroline fosamil for the treatment of patients with community-acquired pneumonia."
4.	Bacteremia 04/01/2017 - "Ceftaroline fosamil monotherapy for methicillin-resistant Staphylococcus aureus bacteremia: a comparative clinical outcomes study." 03/01/2020 - "The practice has led to the question of whether to continue with ceftaroline following bacteremia resolution. " 01/01/2017 - "The utility of ceftaroline for the treatment of methicillin-resistant Staphylococcus aureus bacteremia (MRSAB) is reviewed. " 01/01/2017 - "Ceftaroline for the treatment of methicillin-resistant Staphylococcus aureus bacteremia." 12/01/2016 - "Most patients received at least 4 days of an appropriate anti-MRSA antimicrobial prior to ceftaroline and were able to clear bacteremia within 3 days. "
5.	Bacterial Pneumonia 12/01/2013 - "Pharmacokinetic-pharmacodynamic analyses for efficacy of ceftaroline fosamil in patients with community-acquired bacterial pneumonia." 08/01/2014 - "Contemporary use of ceftaroline fosamil for the treatment of community-acquired bacterial pneumonia: CAPTURE study experience." 12/01/2013 - "Pharmacokinetic-pharmacodynamic (PK-PD) analyses for efficacy using phase III trial data from patients treated with a ceftaroline fosamil dosing regimen of 600 mg intravenously (i.v.) every 12 h (q12h) for 5 to 7 days for community-acquired bacterial pneumonia (CABP) were conducted. " 03/01/2013 - "Assessment of ceftaroline fosamil in the treatment of community-acquired bacterial pneumonia due to Streptococcus pneumoniae: insights from two randomized trials." 12/01/2018 - "To evaluate the potency and spectrum of ceftaroline and comparator agents tested against contemporary bacteria isolated from patients with community-acquired bacterial pneumonia (CABP) in Europe (EUR), Asia-Pacific (APAC), and Latin America (LATAM). "

Related Drugs and Biologics

1.	Vancomycin
2.	Daptomycin
3.	Cephalosporins (Cephalosporin Antibiotics)
4.	Anti-Bacterial Agents (Antibiotics)
5.	Ceftaroline
6.	ceftobiprole
7.	Linezolid (Zyvox)
8.	Prodrugs
9.	avibactam
10.	dalbavancin

Related Therapies and Procedures

1.	Therapeutics
2.	Catheters
3.	Artificial Respiration (Mechanical Ventilation)
4.	Salvage Therapy
5.	Length of Stay